These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 17521218)

  • 1. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
    Gutierrez-Dalmau A; Campistol JM
    Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer and mTOR Inhibitors in Transplant Recipients.
    de Fijter JW
    Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
    Bhat M; Watt KD
    Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
    Klintmalm GB; Saab S; Hong JC; Nashan B
    Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignancy in kidney transplant recipients.
    Kapoor A
    Drugs; 2008; 68 Suppl 1():11-9. PubMed ID: 18442297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review.
    Katabathina VS; Menias CO; Tammisetti VS; Lubner MG; Kielar A; Shaaban A; Mansour J; Surabhi VR; Hara AK
    Radiographics; 2016; 36(5):1390-407. PubMed ID: 27618321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New concepts and best practices for management of pre- and post-transplantation cancer.
    Campistol JM; Cuervas-Mons V; Manito N; Almenar L; Arias M; Casafont F; Del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Román A; Serón D; Ussetti P;
    Transplant Rev (Orlando); 2012 Oct; 26(4):261-79. PubMed ID: 22902168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting malignancy in organ transplant recipients.
    Geissler EK
    Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors.
    Piselli P; Verdirosi D; Cimaglia C; Busnach G; Fratino L; Ettorre GM; De Paoli P; Citterio F; Serraino D
    Best Pract Res Clin Obstet Gynaecol; 2014 Nov; 28(8):1251-65. PubMed ID: 25209964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of proliferation signal inhibitors in post-transplant malignancies.
    Gutiérrez-Dalmau A; Campistol JM
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P; Campistol JM; Diekmann F
    Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mTOR inhibitors in the management of posttransplant malignancy.
    Monaco AP
    Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.